ARCH, Parker Institute build next big oncology bet with suite of programs and startup acquisitionnews2025-12-02T16:34:33+00:00December 2nd, 2025|Endpoints News|
Pazdur’s exit at FDA has biotech afraid of agency ‘tipping point’news2025-12-02T16:33:34+00:00December 2nd, 2025|Endpoints News|
Pfizer culls ulcerative colitis candidate; Tiziana to try spinning out IL-6 drugnews2025-12-02T15:46:30+00:00December 2nd, 2025|Endpoints News|
As approval date looms, Cytokinetics gears up for David-and-Goliath battle with Bristol Myersnews2025-12-02T14:00:46+00:00December 2nd, 2025|Endpoints News|
Helicore stops work on clinical GIP antagonist after Phase 1 resultsnews2025-12-02T13:46:05+00:00December 2nd, 2025|Endpoints News|
Trial Library raises $10M to sell clinical trial matching to insurersnews2025-12-02T13:00:07+00:00December 2nd, 2025|Endpoints News|
Imvax shares Phase 2b data for glioblastoma treatment, plans to meet with FDAnews2025-12-02T11:30:10+00:00December 2nd, 2025|Endpoints News|
Vandria plots Series B raise to advance Alzheimer’s drug into Phase 2news2025-12-02T08:00:53+00:00December 2nd, 2025|Endpoints News|
House passes bill to reauthorize rare pediatric PRV program; Senate nextnews2025-12-02T03:29:54+00:00December 2nd, 2025|Endpoints News|
New ACIP chair claims Covid-19 vaccines caused cancer, miscarriagesnews2025-12-01T21:23:50+00:00December 1st, 2025|Endpoints News|
